MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
QDEL stock logo

QDEL

QuidelOrtho Corporation

$17.25
0.67
 (4.04%)
Exchange:  NASDAQ
Market Cap:  1.174B
Shares Outstanding:  3.333M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Instruments & Supplies
   
CEO:  Brian J. Blaser
Full Time Employees:  6600
Address: 
9975 Summers Ridge Road
San Diego
CA
92121
US
Website:  https://www.quidelortho.com
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/07 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue2,997,8002,782,9002,730,200
Gross Profit1,497,1001,286,5001,274,200
EBITDA607,000-1,489,800-488,100
Operating Income139,100-1,960,900-919,200
Net Income-10,100-2,052,000-1,131,800

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets8,563,1006,423,6005,769,300
Total Liabilities3,557,2003,439,1003,848,800
Total Stockholders Equity5,005,9002,984,5001,920,500
Total Debt2,614,1002,681,4002,804,600
Cash and Cash Equivalents118,90098,300169,800

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow280,20083,000105,200
Capital Expenditure-209,30000
Free Cash Flow70,90083,000105,200
Net Income-10,1000-1,131,800
Net Change in Cash-174,400-21,00071,300

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)3,085,765.672Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)3,122,187.272Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)3,108,123Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)755,849.956Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)764,771.329Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)761,326.323Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)206,371.875Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)209,545.731Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)208,320.003Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)606,052.126Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)613,205.419Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)610,443.161Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)3.100Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)3.120Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)3.070Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
2.785B  ?P/S
 (TTM)
: 
0.32
?Net Income
 (TTM)
: 
-2052000000  ?P/E
 (TTM)
: 
-0.76
?Enterprise Value
 (TTM)
: 
3.5B  ?EV/FCF
 (TTM)
: 
128.21
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.46  ?ROIC
 (TTM)
: 
-0.18
?Net Debt
 (TTM)
: 
2.583B  ?Debt/Equity
 (TTM)
: 
1.46
?P/B
 (TTM)
: 
0.45  ?Current Ratio
 (TTM)
: 
1.5

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
9.86Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates QDEL intrinsic value between $17.55 – $18.17 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate QDEL Intrinsic Value

Common questions about QDEL valuation

Is QuidelOrtho Corporation (QDEL) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for QuidelOrtho Corporation (QDEL) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is QDEL a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether QDEL trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is QDEL’s P/E ratio?

You can see QDEL’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for QDEL?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is QDEL a good long-term investment?

Whether QDEL fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

QDEL

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

4.04
MARKETSnap

Trading Metrics:

Open: 15.89   Previous Close: 16.58
Day Low: 15.55   Day High: 17.55
Year Low: 14.45   Year High: 38.99
Price Avg 50: 22.17   Price Avg 200: 26.36
Volume: 1.138M   Average Volume: 1.881M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Understanding and Addressing Syphilis Trends - and What's Being Missed
23-04-2026 09:32
Understanding and Addressing Syphilis Trends - and What's Being Missed
QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance
15-04-2026 16:15
QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance
Head to Head Comparison: QuidelOrtho (NASDAQ:QDEL) vs. Quipt Home Medical (NASDAQ:QIPT)
01-04-2026 01:10
Head to Head Comparison: QuidelOrtho (NASDAQ:QDEL) vs. Quipt Home Medical (NASDAQ:QIPT)
Why Is QuidelOrtho (QDEL) Down 24.5% Since Last Earnings Report?
13-03-2026 12:36
Why Is QuidelOrtho (QDEL) Down 24.5% Since Last Earnings Report?
Rice Hall James Buys QuidelOrtho Stock
09-03-2026 09:05
Rice Hall James Buys QuidelOrtho Stock
Faster Cardiac Answers with High‑Sensitivity Troponin
19-02-2026 09:17
Faster Cardiac Answers with High‑Sensitivity Troponin

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read